The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Open accessAbstract
So-called super-antibodies are highly potent, broadly reactive antiviral antibodies that offer promise for the treatment of various chronic and emerging viruses. This Review describes how recent technological advances led to their isolation from rare, infected individuals and their development for the prevention and treatment of various viral infections. Antibodies have been used for more than 100 years in the therapy of infectious diseases, but a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies (sometimes referred to as 'super-antibodies') offers new opportunities for intervention. The isolation of these antibodies, most of which are rarely induced in human infections, has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation. Engineering the antibodies to improve half-life and effector functions has further augmented their in vivo activity in some cases. Super-antibodies offer promise for the prophylaxis and therapy of infections with a range of viruses, including those that are highly antigenically variable and those that are newly emerging or that have pandemic potential. The next few years will be decisive in the realization of the promise of super-antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Predominant Autoantibody Production by Early Human B Cell Precursors
Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., & Nussenzweig, M. C. (2003) · Science · doi:10.1126/science.1086907 · Cited by 2,083
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citationBroad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480
Self-citationMascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., et al. (2000) · Nature Medicine · doi:10.1038/72318 · Cited by 1,250
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,139
Self-citationStructural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,130
Sui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L.-M., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1566 · Cited by 1,130
Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C., & Wardemann, H. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.09.017 · Cited by 1,107
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,025
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Highly Conserved Protective Epitopes on Influenza B Viruses
Dreyfus, C., Laursen, N. S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D. C., Lee, J. H., Metlagel, Z., Bujny, M. V., Jongeneelen, M., et al. (2012) · Science · doi:10.1126/science.1222908 · Cited by 866
Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda
Huse, W. D., Sastry, L., Iverson, S. A., Kang, A. S., Alting-Mees, M., Burton, D. R., Benkovic, S. J., & Lerner, R. A. (1989) · Science · doi:10.1126/science.2531466 · Cited by 805
Self-citationEngineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N. S., Louder, M., McKee, K., et al. (2011) · Science · doi:10.1126/science.1207532 · Cited by 784
Self-citationMascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4009-4018.1999 · Cited by 783
Wrammert, J., Koutsonanos, D., Li, G.-M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W. I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101352 · Cited by 777
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Caskey, M., Klein, F., Lorenzi, J. C. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., et al. (2015) · Nature · doi:10.1038/nature14411 · Cited by 767
Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection
Stettler, K., Beltramello, M., Espinosa, D. A., Graham, V., Cassotta, A., Bianchi, S., Vanzetta, F., Minola, A., Jaconi, S., Mele, F., et al. (2016) · Science · doi:10.1126/science.aaf8505 · Cited by 758
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
Lee, J. E., Fusco, M. L., Hessell, A. J., Oswald, W. B., Burton, D. R., & Saphire, E. O. (2008) · Nature · doi:10.1038/nature07082 · Cited by 736
Self-citationDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Parren, P. W. H. I., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., & Burton, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.8340-8347.2001 · Cited by 662
Self-citationEnhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Self-citationSimek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00110-09 · Cited by 594
Self-citationBeltramello, M., Williams, K. L., Simmons, C. P., Macagno, A., Simonelli, L., Quyen, N. T. H., Sukupolvi-Petty, S., Navarro-Sanchez, E., Young, P. R., de Silva, A. M., et al. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.08.007 · Cited by 592
Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus
Priyamvada, L., Quicke, K. M., Hudson, W. H., Onlamoon, N., Sewatanon, J., Edupuganti, S., Pattanapanyasat, K., Chokephaibulkit, K., Mulligan, M. J., Wilson, P. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607931113 · Cited by 587
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
Burton, D. R., & Hangartner, L. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055515 · Cited by 583
Self-citationHessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546
Self-citationAntibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
Structural basis of potent Zika–dengue virus antibody cross-neutralization
Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.-C., Medits, I., Sharma, A., Simon-Lorière, E., Sakuntabhai, A., Cao-Lormeau, V.-M., Haouz, A., et al. (2016) · Nature · doi:10.1038/nature18938 · Cited by 533
Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02036-08 · Cited by 528
Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N. T. H., Duangchinda, T., et al. (2015) · Nature Immunology · doi:10.1038/ni.3058 · Cited by 500
Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I., & Burton, D. R. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000433 · Cited by 497
Self-citationRecurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3389 · Cited by 489
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4268 · Cited by 487
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Scheid, J. F., Horwitz, J. A., Bar-On, Y., Kreider, E. F., Lu, C.-L., Lorenzi, J. C. C., Feldmann, A., Braunschweig, M., Nogueira, L., Oliveira, T., et al. (2016) · Nature · doi:10.1038/nature18929 · Cited by 472
Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C. K., Tumba, N. L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00198-11 · Cited by 466
Lynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Epitopes Involved in Antibody-Mediated Protection from Ebola Virus
Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., & Hart, M. K. (2000) · Science · doi:10.1126/science.287.5458.1664 · Cited by 459
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O. K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M., Lifson, J. D., et al. (2013) · Nature · doi:10.1038/nature12746 · Cited by 455
Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
Murphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 455
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 455
Bonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05045-11 · Cited by 423
Burton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1225416 · Cited by 415
Self-citationImmune history profoundly affects broadly protective B cell responses to influenza
Andrews, S. F., Huang, Y., Kaur, K., Popova, L. I., Ho, I. Y., Pauli, N. T., Dunand, C. J. H., Taylor, W. M., Lim, S., Huang, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0522 · Cited by 411
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Corti, D., Misasi, J., Mulangu, S., Stanley, D. A., Kanekiyo, M., Wollen, S., Ploquin, A., Doria-Rose, N. A., Staupe, R. P., Bailey, M., et al. (2016) · Science · doi:10.1126/science.aad5224 · Cited by 408
Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice
Sapparapu, G., Fernandez, E., Kose, N., Cao, B., Fox, J. M., Bombardi, R. G., Zhao, H., Nelson, C. A., Bryan, A. L., Barnes, T., et al. (2016) · Nature · doi:10.1038/nature20564 · Cited by 408
Li, G.-M., Chiu, C., Wrammert, J., McCausland, M., Andrews, S. F., Zheng, N.-Y., Lee, J.-H., Huang, M., Qu, X., Edupuganti, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118979109 · Cited by 393
Antibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Self-citationEnhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Broad HIV-1 neutralization mediated by CD4-binding site antibodies
Li, Y., Migueles, S. A., Welcher, B., Svehla, K., Phogat, A., Louder, M. K., Wu, X., Shaw, G. M., Connors, M., Wyatt, R. T., et al. (2007) · Nature Medicine · doi:10.1038/nm1624 · Cited by 383
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
Huang, J., Kang, B. H., Ishida, E., Zhou, T., Griesman, T., Sheng, Z., Wu, F., Doria-Rose, N. A., Zhang, B., McKee, K., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.027 · Cited by 369
Sok, D., van Gils, M. J., Pauthner, M., Julien, J.-P., Saye-Francisco, K. L., Hsueh, J., Briney, B., Lee, J. H., Le, K. M., Lee, P. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415789111 · Cited by 364
Self-citationA highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 362
Falkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C., Ramirez, A., Derking, R., van Gils, M. J., Liang, C.-H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.009 · Cited by 359
Self-citationPardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · cited 2×
“Similar proofofconcept studies have also been per formed using synthetic DNA plasmid mediated anti body gene transfer 112, 113 .”
BackgroundDoria-Rose, N. A., Klein, R. M., Daniels, M. G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S. A., Wyatt, R. T., Korber, B. T., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01482-09 · Cited by 336
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
Joyce, M. G., Wheatley, A. K., Thomas, P. V., Chuang, G.-Y., Soto, C., Bailer, R. T., Druz, A., Georgiev, I. S., Gillespie, R. A., Kanekiyo, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.043 · Cited by 333
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico
Robbiani, D. F., Bozzacco, L., Keeffe, J. R., Khouri, R., Olsen, P. C., Gazumyan, A., Schaefer-Babajew, D., Avila-Rios, S., Nogueira, L., Patel, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.024 · Cited by 333
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Macagno, A., Bernasconi, N. L., Vanzetta, F., Dander, E., Sarasini, A., Revello, M. G., Gerna, G., Sallusto, F., & Lanzavecchia, A. (2010) · Journal of Virology · doi:10.1128/jvi.01809-09 · Cited by 326
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
Shingai, M., Donau, O. K., Plishka, R. J., Buckler-White, A., Mascola, J. R., Nabel, G. J., Nason, M. C., Montefiori, D., Moldt, B., Poignard, P., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132494 · Cited by 321
Self-citationHIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Schoofs, T., Klein, F., Braunschweig, M., Kreider, E. F., Feldmann, A., Nogueira, L., Oliveira, T., Lorenzi, J. C. C., Parrish, E. H., Learn, G. H., et al. (2016) · Science · doi:10.1126/science.aaf0972 · Cited by 313
Johnson, P. R., Schnepp, B. C., Zhang, J., Connell, M. J., Greene, S. M., Yuste, E., Desrosiers, R. C., & Reed Clark, K. (2009) · Nature Medicine · doi:10.1038/nm.1967 · Cited by 310
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
Gautam, R., Nishimura, Y., Pegu, A., Nason, M. C., Klein, F., Gazumyan, A., Golijanin, J., Buckler-White, A., Sadjadpour, R., Wang, K., et al. (2016) · Nature · doi:10.1038/nature17677 · Cited by 306
Kwakkenbos, M. J., Diehl, S. A., Yasuda, E., Bakker, A. Q., van Geelen, C. M. M., Lukens, M. V., van Bleek, G. M., Widjojoatmodjo, M. N., Bogers, W. M. J. M., Mei, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2071 · Cited by 300
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 298
Self-citationDetalle, L., Stohr, T., Palomo, C., Piedra, P. A., Gilbert, B. E., Mas, V., Millar, A., Power, U. F., Stortelers, C., Allosery, K., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01802-15 · Cited by 279
Cross-neutralization of four paramyxoviruses by a human monoclonal antibody
Corti, D., Bianchi, S., Vanzetta, F., Minola, A., Perez, L., Agatic, G., Guarino, B., Silacci, C., Marcandalli, J., Marsland, B. J., et al. (2013) · Nature · doi:10.1038/nature12442 · Cited by 278
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Horwitz, J. A., Halper-Stromberg, A., Mouquet, H., Gitlin, A. D., Tretiakova, A., Eisenreich, T. R., Malbec, M., Gravemann, S., Billerbeck, E., Dorner, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315295110 · Cited by 271
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Xu, L., Pegu, A., Rao, E., Doria-Rose, N., Beninga, J., McKee, K., Lord, D. M., Wei, R. R., Deng, G., Louder, M., et al. (2017) · Science · doi:10.1126/science.aan8630 · Cited by 270
Self-citationMolecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In Vivo
Poignard, P., Sabbe, R., Picchio, G. R., Wang, M., Gulizia, R. J., Katinger, H., Parren, P. W. H. I., Mosier, D. E., & Burton, D. R. (1999) · Immunity · doi:10.1016/s1074-7613(00)80043-6 · Cited by 243
Self-citationLee, J. H., Andrabi, R., Su, C.-Y., Yasmeen, A., Julien, J.-P., Kong, L., Wu, N. C., McBride, R., Sok, D., Pauthner, M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.017 · Cited by 239
Self-citationGilman, M. S. A., Castellanos, C. A., Chen, M., Ngwuta, J. O., Goodwin, E., Moin, S. M., Mas, V., Melero, J. A., Wright, P. F., Graham, B. S., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaj1879 · Cited by 238
Self-citationPascal, K. E., Coleman, C. M., Mujica, A. O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C., Strein, J., Berrebi, A., Sisk, J. M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510830112 · Cited by 217
Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., Fernandez-Rodriguez, B., Foglierini, M., Agatic, G., Vanzetta, F., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510199112 · Cited by 216
Wang, Q., Yang, H., Liu, X., Dai, L., Ma, T., Qi, J., Wong, G., Peng, R., Liu, S., Li, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8336 · Cited by 216
A method for identification of HIV gp140 binding memory B cells in human blood
Scheid, J. F., Mouquet, H., Feldhahn, N., Walker, B. D., Pereyra, F., Cutrell, E., Seaman, M. S., Mascola, J. R., Wyatt, R. T., Wardemann, H., et al. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.11.012 · Cited by 214
Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak
Bornholdt, Z. A., Turner, H. L., Murin, C. D., Li, W., Sok, D., Souders, C. A., Piper, A. E., Goff, A., Shamblin, J. D., Wollen, S. E., et al. (2016) · Science · doi:10.1126/science.aad5788 · Cited by 213
Self-citationIdentification and specificity of broadly neutralizing antibodies against HIV
McCoy, L. E., & Burton, D. R. (2017) · Immunological Reviews · doi:10.1111/imr.12484 · Cited by 213
Self-citationStructural and molecular basis for Ebola virus neutralization by protective human antibodies
Misasi, J., Gilman, M. S. A., Kanekiyo, M., Gui, M., Cagigi, A., Mulangu, S., Corti, D., Ledgerwood, J. E., Lanzavecchia, A., Cunningham, J., et al. (2016) · Science · doi:10.1126/science.aad6117 · Cited by 211
A vaccine for HIV type 1: The antibody perspective
Burton, D. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10018 · Cited by 207
Self-citationStevens, R. H., Macy, E., Morrow, C., & Saxon, A. (1979) · The Journal of Immunology · doi:10.4049/jimmunol.122.6.2498 · Cited by 199
Flyak, A. I., Shen, X., Murin, C. D., Turner, H. L., David, J. A., Fusco, M. L., Lampley, R., Kose, N., Ilinykh, P. A., Kuzmina, N., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.022 · Cited by 187
Immune history shapes specificity of pandemic H1N1 influenza antibody responses
Li, Y., Myers, J. L., Bostick, D. L., Sullivan, C. B., Madara, J., Linderman, S. L., Liu, Q., Carter, D. M., Wrammert, J., Esposito, S., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130212 · Cited by 184
Lee, E.-C., Liang, Q., Ali, H., Bayliss, L., Beasley, A., Bloomfield-Gerdes, T., Bonoli, L., Brown, R., Campbell, J., Carpenter, A., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2825 · Cited by 182
Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection
Sommerstein, R., Flatz, L., Remy, M. M., Malinge, P., Magistrelli, G., Fischer, N., Sahin, M., Bergthaler, A., Igonet, S., ter Meulen, J., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005276 · Cited by 174
Wu, N. C., & Wilson, I. A. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.06.015 · Cited by 174
Monoclonal antibody-based therapies for microbial diseases
Saylor, C., Dadachova, E., & Casadevall, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.105 · Cited by 172
Van Heeke, G., Allosery, K., De Brabandere, V., De Smedt, T., Detalle, L., & de Fougerolles, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.012 · Cited by 171
Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows
Sok, D., Le, K. M., Vadnais, M., Saye-Francisco, K. L., Jardine, J. G., Torres, J. L., Berndsen, Z. T., Kong, L., Stanfield, R., Ruiz, J., et al. (2017) · Nature · doi:10.1038/nature23301 · Cited by 171
Self-citationRobinson, J. E., Hastie, K. M., Cross, R. W., Yenni, R. E., Elliott, D. H., Rouelle, J. A., Kannadka, C. B., Smira, A. A., Garry, C. E., Bradley, B. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11544 · Cited by 169
Isolation of human monoclonal antibodies from peripheral blood B cells
Huang, J., Doria-Rose, N. A., Longo, N. S., Laub, L., Lin, C.-L., Turk, E., Kang, B. H., Migueles, S. A., Bailer, R. T., Mascola, J. R., et al. (2013) · Nature Protocols · doi:10.1038/nprot.2013.117 · Cited by 168
Wec, A. Z., Herbert, A. S., Murin, C. D., Nyakatura, E. K., Abelson, D. M., Fels, J. M., He, S., James, R. M., de La Vega, M.-A., Zhu, W., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.037 · Cited by 164
Self-citationErythropoietin gene therapy leads to autoimmune anemia in macaques
Gao, G., Lebherz, C., Weiner, D. J., Grant, R. L., Calcedo, R., McCullough, B. A., Bagg, A., Zhang, Y., & Wilson, J. M. (2003) · Blood · doi:10.1182/blood-2003-11-3852 · Cited by 155
History of passive antibody administration for prevention and treatment of infectious diseases
Graham, B. S., & Ambrosino, D. M. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000154 · Cited by 155
Tools to therapeutically harness the human antibody response
Wilson, P. C., & Andrews, S. F. (2012) · Nature reviews. Immunology · doi:10.1038/nri3285 · Cited by 152
A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential
Wang, J., Bardelli, M., Espinosa, D. A., Pedotti, M., Ng, T., Bianchi, S., Simonelli, L., Lim, E. X. Y., Foglierini, M., Zatta, F., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.002 · Cited by 149
Yu, X., Robbie, G. J., Wu, Y., Esser, M. T., Jensen, K. M., Schwartz, H. I., Bellamy, T., Hernandez‐Illas, M., & Jafri, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-16 · Cited by 147
Smith, S. A., Silva, L. A., Fox, J. M., Flyak, A. I., Kose, N., Sapparapu, G., Khomandiak, S., Ashbrook, A. W., Kahle, K. M., Fong, R. H., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.06.009 · Cited by 143
Tackling influenza with broadly neutralizing antibodies
Corti, D., Cameroni, E., Guarino, B., Kallewaard, N. L., Zhu, Q., & Lanzavecchia, A. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.002 · Cited by 139
Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail
Jülg, B. D., Liu, P.-T., Wagh, K., Fischer, W., Abbink, P., Mercado, N. B., Whitney, J. B., Nkolola, J. P., McMahan, K., Tartaglia, L. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4235 · Cited by 139
Self-citationBabcook, J. S., Leslie, K. B., Olsen, O. A., Salmon, R. A., & Schrader, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7843 · Cited by 132
Burton, D. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a030262 · Cited by 132
Self-citationTherapeutic antibodies for infectious diseases
Sparrow, E. G., Friede, M., Sheikh, M., & Torvaldsen, S. (2017) · Bulletin of the World Health Organization · doi:10.2471/blt.16.178061 · Cited by 127
Zhao, X., Howell, K. A., He, S., Brannan, J. M., Wec, A. Z., Davidson, E., Turner, H. L., Chiang, C.-I., Lei, L., Fels, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.038 · Cited by 126
Falkowska, E., Ramos, A. G., Feng, Y., Zhou, T., Moquin, S. A., Walker, L. M., Wu, X., Seaman, M. S., Wrin, T., Kwong, P. D., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06973-11 · Cited by 122
Self-citationPriyamvada, L., Cho, A., Onlamoon, N., Zheng, N., Huang, M., Kovalenkov, Y. O., Chokephaibulkit, K., Angkasekwinai, N., Pattanapanyasat, K., Ahmed, R., et al. (2016) · Journal of Virology · doi:10.1128/jvi.03203-15 · Cited by 121
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo
Luke, T. C., Wu, H., Zhao, J., Channappanavar, R., Coleman, C. M., Jiao, J., Matsushita, H., Liu, Y., Postnikova, E. N., Ork, B. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1061 · Cited by 116
Saunders, K. O., Pegu, A., Georgiev, I. S., Zeng, M., Joyce, M. G., Yang, Z., Ko, S., Chen, X., Schmidt, S. D., Haase, A. T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00210-15 · Cited by 111
Andrews, S. F., Joyce, M. G., Chambers, M. J., Gillespie, R. A., Kanekiyo, M., Leung, K., Yang, E. S., Tsybovsky, Y., Wheatley, A. K., Crank, M. C., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan2676 · Cited by 111
Jülg, B. D., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D., Abbink, P., Schmidt, S. D., Wang, K., Chen, X., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal1321 · Cited by 107
Self-citationDevelopment of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis
De Benedictis, P., Minola, A., Rota Nodari, E., Aiello, R., Zecchin, B., Salomoni, A., Foglierini, M., Agatic, G., Vanzetta, F., Lavenir, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505986 · Cited by 103
Qiu, X., Fernando, L., Melito, P. L., Audet, J., Feldmann, H., Kobinger, G., Alimonti, J. B., & Jones, S. M. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001575 · Cited by 98
Wen, X., Mousa, J. J., Bates, J. T., Lamb, R. A., Crowe, J. E., & Jardetzky, T. S. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.272 · Cited by 98
Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors
Rogers, T. F., Goodwin, E. C., Briney, B. S., Sok, D., Beutler, N., Strubel, A., Nedellec, R., Le, K. M., Brown, M. E., Burton, D. R., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan6809 · Cited by 97
Self-citationRossey, I., Gilman, M. S. A., Kabeche, S. C., Sedeyn, K., Wrapp, D., Kanekiyo, M., Chen, M., Más, V., Spitaels, J., Melero, J. A., et al. (2017) · Nature Communications · doi:10.1038/ncomms14158 · Cited by 92
Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques
Magnani, D. M., Rogers, T. F., Beutler, N., Ricciardi, M. J., Bailey, V. K., Gonzalez-Nieto, L., Briney, B. S., Sok, D., Le, K. M., Strubel, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8184 · Cited by 92
Self-citationHistory and Practice: Antibodies in Infectious Diseases
Hey, A. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0026-2014 · Cited by 91
Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology
Berry, J. D., & Gaudet, R. G. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.018 · Cited by 87
Human monoclonal antibodies by immortalization of memory B cells
Lanzavecchia, A., Corti, D., & Sallusto, F. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.011 · Cited by 81
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy
Flingai, S., Plummer, E. M., Patel, A. R., Shresta, S., Mendoza, J. M., Broderick, K. E., Sardesai, N. Y., Muthumani, K., & Weiner, D. B. (2015) · Scientific Reports · doi:10.1038/srep12616 · Cited by 76
Hooper, J. W., Brocato, R. L., Kwilas, S. A., Hammerbeck, C. D., Josleyn, M. D., Royals, M. A., Ballantyne, J. A., Wu, H., Jiao, J., Matsushita, H., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010082 · Cited by 75
Paules, C. I., Lakdawala, S. S., McAuliffe, J. M., Paskel, M., Vogel, L., Kallewaard, N. L., Zhu, Q., & Subbarao, K. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix292 · Cited by 71
Scherer, E. M., Smith, R. A. J., Simonich, C. A. L., Niyonzima, N., Carter, J. J., & Galloway, D. A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004461 · Cited by 68
Monoclonal Antibodies Produced by Muscle after Plasmid Injection and Electroporation
Tjelle, T. E., Corthay, A., Lunde, E., Sandlie, I., Michaelsen, T. E., Mathiesen, I., & Bogen, B. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.007 · Cited by 66
Schepens, B., Ibañez, L. I., Baets, S. D., Hultberg, A., Bogaert, P., Bleser, P. D., Vervalle, F., Verrips, T. C., Melero, J. A., Vandevelde, W., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir622 · Cited by 64
Prabakaran, M., Prabhu, N., He, F., Hongliang, Q., Ho, H.-T., Jia, Q., TaoMeng, Goutama, M., & Kwang, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005672 · Cited by 62
Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor
Chen, Z., Fischer, E. R., Kouiavskaia, D. V., Hansen, B. T., Ludtke, S. J., Bidzhieva, B., Makiya, M. A., Agulto, L., Purcell, R. H., & Chumakov, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320041110 · Cited by 54
Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia
Medina-Ramírez, M., Sánchez-Merino, V., Sánchez‐Palomino, S., Merino-Mansilla, A., Ferreira, C. B., Pérez, I., Gonzàlez, N., Alvarez, A., Alcocer-González, J. M., García, F., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02482-10 · Cited by 47
Muthumani, K., Flingai, S., Wise, M. C., Tingey, C., Ugen, K. E., & Weiner, D. B. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26498 · Cited by 47
Silveira, E. L. V., Kasturi, S. P., Kovalenkov, Y. O., Rasheed, A. U., Yeiser, P., Sher, Z. J., Legere, T. H., Pulendran, B., Villinger, F. J., & Wrammert, J. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.11.003 · Cited by 46
Gardner, C. L., Sun, C., Luke, T. C., Raviprakash, K. S., Wu, H., Jiao, J., Sullivan, E. J., Reed, D. S., Ryman, K. D., & Klimstra, W. B. (2017) · Journal of Virology · doi:10.1128/jvi.00226-17 · Cited by 39
Vectored antibody gene delivery for the prevention or treatment of HIV infection
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000145 · Cited by 37
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230
Self-citationSARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far
Rabi, F. A., Al Zoubi, M. S., Kasasbeh, G. A., Salameh, D. M., & Al-Nasser, A. D. (2020) · Pathogens · doi:10.3390/pathogens9030231 · Cited by 775
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R., & De Clercq, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 676
COVID-19: A promising cure for the global panic
Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., et al. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138277 · Cited by 636
Metadata
- Authors
- Walker, L. M., & Burton, D. R.
- Venue
- Nature Reviews Immunology
- Published
- 2018-01-30
- Volume
- 18
- Issue
- 5
- Pages
- 297-308
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2786695043
- Cited by
- 268
- References
- 148
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.